Printed From:

Hypothetical patient profile. Individual results may vary.

How to initiate and titrate Toujeo® to individualized goal

T2DM Dosing Calculator

Determine a patient's starting dose based on body weight1,a Enter a patient's weight (lbs)—to calculate the recommended starting dose

Weight in pounds

The starting dose of Toujeo® is based on prior treatment1

 

Insulin-naive

Weight-based insulin-naive

 

Once-daily basal

 

of total daily NPH dose

Titrate according to patients' specific needs and history

FPG, fasting plasma glucose; NPH, neutral pH.

ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.

More or less stringent goals may be appropriate for individual patients.2

ADA glycemic recommendations for fasting or pre-meal plasma glucose for non-pregnant adults with diabetes: 80-130 mg/dL.More or less stringent goals may be appropriate for individual patients.2

In clinical trials, patients started on, or changed to, Toujeo® required a higher dose than patients controlled with Lantus®.

Ensure patients have a prescription for Toujeo® as well as a second, separate prescription for pen needles.

Prescribe the experience of the Toujeo® SoloStar® Pen

In a study,
95%
of new start basal insulin patients rated Toujeo® SoloStar® as easy to use after training and 4 weeks of use3,a

It is important to train patients on proper product administration

Unopened pens should be stored in a refrigerator (between 36°F and 46°F) until the expiration date; when opened, store at room temperature (below 86°F)

Study Design

aPen- and insulin-naive T2DM patients inadequately controlled on OADs were enrolled in a 4-week, multicenter, open-label, single-arm, phase 3b study to evaluate the ease of use/ease of learning of the Toujeo® SoloStar® pen. On Day 1, patients were trained on use of the device. Only patients who completed the training and demonstrated a successful injection without assistance were eligible for this study (n=40). Toujeo® was injected once-daily in the evening. Patients were titrated to a target SMPG of 80-100 mg/dL. Study limitations: potential bias could have been introduced due to the small population and the study's short duration; however, the study was designed to minimize such bias.3

Adding Toujeo® SoloStar® pen to your Electronic Medical Record (EMR) system

Toujeo® SoloStar®:

  • NDC: 0024-5869-03
  • 300 Units/mL formulation
  • 1.5 mL and 450 Units per pen
  • 3 pens (4.5 mL and 1350 Units total) per box

Determine how many boxes of Toujeo® SoloStar® a patient will need for a 30-day supply

1 box provides ... Up to 45 Units/day (total supply dispensed: 4.5 mL)
2 boxes provide ... 46-90 Units/day (total supply dispensed: 9 mL)
3 boxes provide ... 91-135 Units/day (total supply dispensed: 13.5 mL)

Clinical Profile

Explore the pharmacology and efficacy and safety of Toujeo®

Learn more

Coverage and Savings

See how your patients can save with Toujeo®

See local coverage

References: 1. Toujeo Prescribing Information. 2. American Diabetes Association. Diabetes Care. 2017;40(suppl 1):S1-S135. 3. Pohlmeier H, Berard L, Brulle-Wohlhueter C, et al. J Diabetes Sci Technol. 2016;11(2):263-269. 4. Toujeo Instructions for Use. 5. Klonoff D, Nayberg I, Erbstein F, Cali A, Brulle-Wohlhueter C, Haak T. J Diabetes Sci Technol. 2015;9(4):936-938